Long-term evolution of multiple sclerosis disability in the treatment era

Annals of Neurology

Volumn 80, Issue 4, 2016, Pages 499-510

  Cree, Bruce A C ^a   Gourraud, Pierre Antoine ^a   Oksenberg, Jorge R ^a   Bevan, Carolyn ^a   Crabtree Hartman, Elizabeth ^a   Gelfand, Jeffrey M ^a   Goodin, Douglas S ^a   Graves, Jennifer ^a   Green, Ari J ^a   Mowry, Ellen ^a   Okuda, Darin T ^b   Pelletier, Daniel ^c   von Büdingen, H Christian ^a   Zamvil, Scott S ^a   Agrawal, Alisha ^a   Caillier, Stacy ^a   Ciocca, Caroline ^a   Gomez, Refujia ^a   Kanner, Rachel ^a   Lincoln, Robin ^a   Lizee, Antoine ^a   Qualley, Pamela ^a   Santaniello, Adam ^a   Suleiman, Leena ^a   Bucci, Monica ^a   Panara, Valentina ^a   Papinutto, Nico ^a   Stern, William A ^a   Zhu, Alyssa H ^a   Cutter, Gary R ^d   Baranzini, Sergio ^a   Henry, Roland G ^a   Hauser, Stephen L ^a   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; AZATHIOPRINE; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; GLUCOCORTICOID; INTERFERON BETA SERINE; MITOXANTRONE; MYCOPHENOLATE MOFETIL; NATALIZUMAB; RITUXIMAB; TERIFLUNOMIDE;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CHRONIC PATIENT; CLINICAL OUTCOME; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DISABILITY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG PULSE THERAPY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OFF LABEL DRUG USE; ONSET AGE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGNOSTIC ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; VITAMIN BLOOD LEVEL; DIAGNOSTIC IMAGING; DISABLED PERSON; DISEASE COURSE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ADULT; DISABLED PERSONS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84981320947     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24747     Document Type: Article

References (54)

1. Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430–1438.
2. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003;126:770–782.
3. Tremlett H, Paty D, Devonshire V. The natural history of primary progressive MS in British Columbia, Canada. Neurology 2005;65:1919–1923.
4. Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006;66:172–177.
5. Debouverie M, Pittion-Vouyovitch S, Louis S, et al. Natural history of multiple sclerosis in a population-based cohort. Eur J Neurol 2008;15:916–921.
6. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003;61:1528–1532.
7. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014;83:278–286.
8. O'Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998;121:495–503.
9. Rudick RA, Lee JC, Nakamura K, et al. Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. J Neurol Sci 2009;282:106–111.
10. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121–127.
11. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292–302.
12. Lassmann H, van Horssen J, Mahad D Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012;8:647–656.
13. International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476:214–219.
14. Nickles D, Chen HP, Li MM, et al. Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls. Hum Mol Genet 2013;22:4194–4205.
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–1452.
16. Rudick RA, Cutter G, Reingold S. The multiple sclerosis functional composite: a new clinical outcome measure for multiple sclerosis trials. Mult Scler 2002;8:359–365.
17. Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:545–556.
18. Kaufman M, Moyer D, Norton J. The significant change for the Timed 25-foot Walk in the multiple sclerosis functional composite. Mult Scler 2000;6:286–290.
19. Ytterberg C, Johansson S, Andersson M, et al. Variations in functioning and disability in multiple sclerosis. A two-year prospective study. J Neurol 2008;255:967–973.
20. Barker-Collo SL, Purdy SC. Determining the presence of reliable change over time in multiple sclerosis: evidence from the PASAT, Adjusting-PSAT, and Stroop Test. Int J MS Care 2013;15:170–178.
21. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907–911.
22. Massacesi L, Tramacere I, Amoroso S, et al. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. PLoS One 2014;9:e113371.
23. Michel L, Vukusic S, De Seze J, et al. Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients. J Neurol Neurosurg Psychiatry 2014;85:279–283.
24. Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2000;57:1239–1247.
25. Oh J, O'Connor PW. Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects. Ther Adv Neurol Disord 2014;7:239–252.
26. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911–923.
27. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011;378:1779–1787.
28. Vollmer T, Panitch H, Bar-Or A, et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 2008;14:663–670.
29. Castillo-Trivino T, Mowry EM, Gajofatto A, et al. Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS One 2011;6:e16664.
30. Bevan CJ, Cree BA. Disease activity free status: a new end point for a new era in multiple sclerosis clinical research? JAMA Neurol 2014;7:269–270.
31. Lublin FD, Cofield SS, Cutter GR, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol 2013;73:327–340.
32. Gourraud PA, McElroy JP, Caillier SJ, et al. Aggregation of multiple sclerosis genetic risk variants in multiple and single case families. Ann Neurol 2011;69:65–74.
33. Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296:2832–2838.
34. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227–231.
35. Mowry EM, Waubant E, McCulloch CE, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 2012;72:234–240.
36. Ascherio A, Munger KL, White R, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 2014;71:306–314.
37. Gelfand JM, Cree BA, McElroy J, et al. Vitamin D in African Americans with multiple sclerosis. Neurology 2011;76:1824–1830.
38. Tremlett H, Zhao Y, Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler 2008;14:314–324.
39. Debouverie M, Laforest L, Van Ganse E, et al. Earlier disability of the patients followed in multiple sclerosis centers compared to outpatients. Mult Scler 2009;15:251–257.
40. Tedeholm H, Skoog B, Lisovskaja V, et al. The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset. J Neurol 2015;262:1148–1163.
41. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 2007;6:300–306.
42. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112(pt 1):133–146.
43. Bermel RA, You X, Foulds P, et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon β. Ann Neurol 2013;73:95–103.
44. Prosperini L, Gallo V, Petsas N, et al. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol 2009;16:1202–1209.
45. Romeo M, Martinelli-Boneschi F, Rodegher M, et al. Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients. Eur J Neurol 2013;20:1060–1067.
46. Goodin DS, Traboulsee A, Knappertz V, et al. Relationship between early clinical characteristics and long-term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry 2012;83:282–287.
47. Brown MG, Asbridge M, Hicks V, et al. Estimating typical multiple sclerosis disability progression speed from clinical observations. PLoS One 2014;9:e105123.
48. Ebers GC, Heigenhauser L, Daumer M, et al. Disability as an outcome in MS clinical trials. Neurology 2008;71:624–631.
49. Rotstein DL, Healy BC, Malik MT, et al. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol 2015;72:152–158.
50. Kappos L, De Stefano N, Freedman MS, et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler 2015 [Epub ahead of print].
51. Daumer M, Neuhaus A, Morrissey S, et al. MRI as an outcome in multiple sclerosis clinical trials. Neurology 2009;72:705–711.
52. Cook SD, Dhib-Jalbut S, Dowling P, et al. Use of magnetic resonance imaging as well as clinical disease activity in the clinical classification of multiple sclerosis and assessment of its course: a report from an International CMSC Consensus Conference, March 5–7, 2010. Int J MS Care 2012;14:105–114.
53. Schlaeger R, Papinutto N, Panara V, et al. Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol 2014;76:568–580.
54. Schlaeger R, Papinutto N, Zhu AH, et al. Association between thoracic spinal cord gray matter atrophy and disability in multiple sclerosis. JAMA Neurol 2015;72:897–904.